---
title: "Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287272414.md"
description: "Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News"
datetime: "2026-05-21T13:00:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287272414.md)
  - [en](https://longbridge.com/en/news/287272414.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287272414.md)
---

# Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News

### Related Stocks

- [BCYC.US](https://longbridge.com/en/quote/BCYC.US.md)

## Related News & Research

- [Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC](https://longbridge.com/en/news/287274269.md)
- [Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | BCYC Stock News](https://longbridge.com/en/news/283520201.md)
- [Are Daiichi Sankyo Company’s (TSE:4568) ASCO 2026 ADC Data Deepening Its Oncology Moat?](https://longbridge.com/en/news/288948995.md)
- [<![CDATA[What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson from EVERSANA]]>](https://longbridge.com/en/news/288700390.md)
- [ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | TLX Stock News](https://longbridge.com/en/news/288327814.md)